⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Aitia and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Aitia
↗Somerville, Massachusetts, USA
Aitia is a leading AI-enabled biotechnology company that leverages causal AI and its proprietary 'Gemini Digital Twins' platform to simulate human disease biology. By integrating massive patient multiomics and clinical datasets, the company identifies novel drug targets and accelerates drug discovery across oncology, neurodegeneration, and other high-unmet-need therapeutic areas.
Formerly known as GNS Healthcare, the company rebranded to Aitia in 2023 to emphasize its shift from an AI service provider to a drug discovery-focused biotech. Aitia partners with major pharmaceutical companies to validate targets and develop drug candidates, aiming to transform the efficiency and success rates of pharmaceutical R&D.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Ownership:private
Status:operating
FUNDING
Stage:Venture Capital-Backed
PIPELINE
Stage:Discovery
Lead Drug Stage:Discovery/Preclinical
Modalities:Small molecule, Target discovery
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Servier (Oncology/Glioma), Orion Corporation (Oncology), UCB (Huntington's disease), Gustave Roussy (Oncology)
COMPETITION
Position:Emerging
Competitors:Caris Life Sciences
LEADERSHIP
Key Executives:
Colin Hill - CEO and Co-founder
Jean-Michel Gries - President & COO
LINKS
Website:aitia.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Aitia. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.